About Mellitus
Mellitus is a Healthcare company based in Boston (United States) founded in 2011. It operates as an in vitro diagnostic test for Gestational Diabetes Mellitus (GDM). Mellitus has raised $16.1 million across 10 funding rounds. Mellitus offers products and services including Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja. Its focus areas include Life Sciences, Diabetes and In-Vitro Diagnostics. Its competitors include Viome Life Sciences, Proteomics International, Tethys BioScience, SmartZyme and Veralight and 3 more; 5 of its 8 listed competitors have raised funding.
Company details
Mellitus was founded in 2011 in Boston, United States, within the biotechnology sector. An in vitro diagnostic assay for diabetes is being developed, drawing on technology licensed from Harvard University. The lead candidate measures the Glycated CD59 biomarker and targets screening, diagnosis, and monitoring of Gestational Diabetes Mellitus. Applications as a companion diagnostic for pharmaceutical development are also pursued.
- Headquarters Boston, United States
- SectorsHealthcare
- Website mellitusllc.com
- Social LinkedIn
- Total Equity Funding$16.1M (USD)
in 10 rounds
- Latest Funding Round$2.8M (USD), Series A
May 2019
Products & Services of Mellitus
Mellitus offers a comprehensive portfolio of products and services, including Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja.
Provides official Cambodian lottery results for betting analysis.
Offers real-time draws for accurate lottery outcomes.
Delivers daily lottery output for user predictions.
Compiles historical data for lottery trend analysis.
Funding Insights of Mellitus
Mellitus has successfully raised a total of $16.1M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $2.8 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.1M
- Total Rounds 10
- Last Round Series A — $2.8M
- First Round $2.22M
(Oct 2013)
All 10 funding rounds of Mellitus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $2.8M | Series A | – | – | – |
| Sep 2018 | $1.68M | Series A | – | – | – |
| Jul 2018 | $1.75M | Series A | – | – | – |
| Apr 2018 | $5.59M | Series A | – | – | – |
| May 2017 | $2.07M | Seed | – | – | – |
| May 2016 | $992,883 | Debt – Conventional | – | – | – |
| Jan 2016 | $50,000 | Debt – Conventional | – | – | – |
| Sep 2015 | $150,000 | Debt – Conventional | – | – | – |
| Aug 2015 | $558,934 | Debt – Conventional | – | – | – |
| Oct 2013 | $2.22M | Seed | – | – | – |
People of Mellitus
8 people are tracked at Mellitus (2 in leadership, 5 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Rick Saul | Head of Product Development | Leadership |
Kathy Welch | Head of Finance | Leadership |
Christopher De Souza | Board Member | Board & advisors |
Jose A. Halperin | Co-Founder & Board Member | Board & advisors |
Thomas J. Musci | Clinical Advisor | Board & advisors |
Michael Chorev | Co-Founder & Board Member | Board & advisors |
Ellie McGuire | Board Member | Board & advisors |
Jing Shi | Principal Scientist | Team |
Complete people profiles for Mellitus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mellitus
3 dated milestones of Mellitus across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Mellitus is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Series A, of $2.8M.
Competitors of Mellitus
Mellitus has 8 listed competitors in our database, 5 of them funded. They include Viome Life Sciences, Proteomics International, Tethys BioScience, SmartZyme and Veralight, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| proteomics.com.au | 2001 | Perth, Australia | – | – | Medical technology company at the forefront of predictive diagnostics and bio-analytical services | |
| tethysbio.com | 2002 | Emeryville, United States | $53.3M | 81 | Develops biological markers for medical diagnostic applications. | |
| smzyme.com | 2013 | Herzliya Pituach, Israel | $4M | – | Proprietary protein engineering technology is developed for diabetes products. | |
| thescoutds.com | 2004 | Albuquerque, United States | $25.23M | – | Offers biomarker screening solutions for early diabetes detection. | |
| sensotrend.com | 2013 | Tampere, Finland | – | – | Automated diabetes diary is offered for blood sugar monitoring. | |
| quotientdiagnostics.co.uk | 2003 | – | $1.41M | 1 | Glycated haemoglobin analysers are developed to monitor diabetes treatment. | |
| enanohealth.com | 2010 | Hong Kong, China | – | – | Developer of suite of diagnostics products |
Detailed competitors of Mellitus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as Mellitus (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mellitus
Complete news archive for Mellitus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mellitus
Mellitus was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Mellitus is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Mellitus is a funded company, having raised a total of $16.1M across 10 funding rounds to date. The company's 1st funding round was a Seed of $2.22M, raised on Oct 2013.
Mellitus was founded in 2011 in Boston, United States, within the biotechnology sector. An in vitro diagnostic assay for diabetes is being developed, drawing on technology licensed from Harvard University. The lead candidate measures the Glycated CD59 biomarker and targets screening, diagnosis, and monitoring of Gestational Diabetes Mellitus. Applications as a companion diagnostic for pharmaceutical development are also pursued.
Mellitus's top competitors include Viome Life Sciences, Proteomics International and SmartZyme.
Mellitus offers Pengeluaran Cambodia, Live Draw Cambodia, Keluaran Kamboja, and Tabel Data Kamboja.